StreetInsider.com News Articles

Form 8-K CUMBERLAND PHARMACEUTICA For: Aug 28

Fri, 28 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260828/26999003.html

Form 8-K CUMBERLAND PHARMACEUTICA For: Aug 28

Fri, 28 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260828/26999003.html

Form 10-Q CUMBERLAND PHARMACEUTICA For: Jun 30

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892172.html

Form 10-Q CUMBERLAND PHARMACEUTICA For: Jun 30

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892172.html

Cumberland Pharmaceuticals (CPIX) Reports Q2 Loss of $0.20

Tue, 04 Aug 2026 17:57:28 -0400

Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q2 EPS of ($0.20). Revenue for the quarter came in at $166.45 million.

For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.

Form 8-K CUMBERLAND PHARMACEUTICA For: Aug 04

Tue, 04 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260804/26868042.html

Form 8-K CUMBERLAND PHARMACEUTICA For: Aug 04

Tue, 04 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260804/26868042.html

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health.

During the second quarter, Cumberland completed a transaction with Apotex Health, the largest Canadian pharmaceutical company, to integrate their branded business. Under the terms of the agreement, Apotex acquired Cumberland's portfolio of FDA-approved brands

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 28 Jul 2026 16:05:00 -0400

NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.

A conference call will be held on August 4 at 4:30 p.m. Eastern Time to discuss the results and update.

Call Participation

The link to register is https://register-conf.media-server.com/register/BI2da176d5d0dd4778a44db3d4af6e7b39.

Once registered, participants can dial in from their phone using a dial-in and PIN number

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 28 Jul 2026 16:05:00 -0400

A conference call will be held on August 4 at 4:30 p.m. Eastern Time to discuss the results and update.

Call Participation

The link to register is https://register-conf.media-server.com/register/BI2da176d5d0dd4778a44db3d4af6e7b39.

Once registered, participants can dial in from their phone using a dial-in and PIN number

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 28 Jul 2026 16:05:00 -0400

A conference call will be held on August 4 at 4:30 p.m. Eastern Time to discuss the results and update.

Call Participation

The link to register is https://register-conf.media-server.com/register/BI2da176d5d0dd4778a44db3d4af6e7b39.

Once registered, participants can dial in from their phone using a dial-in and PIN number

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 28 Jul 2026 16:05:00 -0400

A conference call will be held on August 4 at 4:30 p.m. Eastern Time to discuss the results and update.

Call Participation

The link to register is https://register-conf.media-server.com/register/BI2da176d5d0dd4778a44db3d4af6e7b39.

Once registered, participants can dial in from their phone using a dial-in and PIN number

Form 8-K CUMBERLAND PHARMACEUTICA For: Jul 13

Mon, 13 Jul 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260713/26763301.html

Form 8-K CUMBERLAND PHARMACEUTICA For: Jul 13

Mon, 13 Jul 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260713/26763301.html

Cumberland Pharmaceuticals declares $1.50 special dividend after Apotex deal

Mon, 13 Jul 2026 11:00:24 -0400

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has declared a special cash dividend of $1.50 per share of common stock, payable July 31, 2026, to shareholders of record as of July 10, 2026.

The dividend follows the company's previously announced transaction with Apotex Health, in which Cumberland received $100 million in cash for its line of FDA-approved products. Cumberland also expects to receive up to $11 million in additional payments tied to product inventory and transitional support services.

According to the company, analysis by its tax advisors and updated financial projections indicated greater net cash from the transaction than originally expected, prompting the board

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Mon, 13 Jul 2026 10:46:00 -0400

Record Date is July 10, 2026 & Payment Date is July 31,2026

Corporate and Insider Share Purchase Initiatives to Continue

NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend will be payable on July 31, 2026, to the shareholders of record at the close of business on July 10, 2026.

Cumberland previously announced

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Mon, 13 Jul 2026 10:46:00 -0400

Record Date is July 10, 2026 & Payment Date is July 31,2026

Corporate and Insider Share Purchase Initiatives to Continue

Cumberland previously announced

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Mon, 13 Jul 2026 10:46:00 -0400

Record Date is July 10, 2026 & Payment Date is July 31,2026

Corporate and Insider Share Purchase Initiatives to Continue

Cumberland previously announced